Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.
The findings showed that the proportion of patients who achieved a partial response or better was 50% for the HER-Vaxx group, compared to 29% for those who received chemotherapy alone.
https://beta.firstwordpharma.com/story/5342463
two monoclonal antibodies: AL001 and AL101
https://www.fiercebiotech.com/biotech/gsk-under-pressure-to-perform-pens-2-2b-deal-alector-focused-neuro-r-d-alzheimer-s
Thanks Konar, it sounds good.
Scancell have developed a fast, low cost and effective DNA vaccine which stimulates potent immune responses that can kill cancer cells and has already been shown to be safe and effective in the treatment of patients with skin cancer. This approach can also be used to develop a safe and effective vaccine to prevent infection with viruses such as the coronavirus that causes COVID-19. Like other vaccines being developed, the Scancell one will help the body to make antibodies to stop the COVID-19 virus getting into cells and causing the person to become infected. What makes this vaccine different from other approaches is that it will also stimulate the immune system to make special T cells that can recognise and kill cells that may have been infected with the virus. These T cells will also remain in the body longer than antibodies and be there in case of future infections. As all adults in the UK will have been offered a COVID-19 vaccine by the end of July 2021, the proposed Scancell COVID-19 vaccine will be administered to healthy volunteers who have already had two doses of an approved vaccine to see if this boosts their responses. Scancell’s first vaccine (SN15) will initially be given using a process called electroporation which delivers the DNA with a mild electric shock to increase efficacy. Although this approach worked well in cancer patients it requires an expensive device to deliver the vaccine. This is not practical when millions of healthy subjects will need to be immunised as during the current pandemic. To overcome this problem, we will also test a needle-free injection device which is much easier to use. Scancell has also developed a second vaccine, SN17, which targets the new variants such as the Kent, Brazilian and South African ones. Volunteers will receive boost injections with this vaccine to test if this increases the responses against these new virus variants.
Well hopefully the cancer trials begin within the next couple of months and then we will know the answer!
Scancell could even become a lead player in the landscape, if Professor Durrant’s optimism is well-placed.
“SCIB1 is in the clinic and it’s working,” she said. “Moditope is a different way of looking at things. In animals, it’s been amazing, but it needs to work in humans. It could be huge, it could be small – hopefully it’s significant.”
http://www.pharmafile.com/news/581482/booster-jabs-planned-over-50s-september
Super post Burble, thank you.
What made me invest was the fact that Scib 1 had shown promising results. I agree that the potential is huge.
Re CrispR, In relation to our mABS , the Car T FL134 candidate, maybe the next big development there could be In Vivo.
Base editing is having some success and appears to be more accurate.
(This proprietary combination enables the precise targeting and editing of a single base pair of DNA, which has not been previously possible to our knowledge.)
https://beamtx.com/our-science/
Base editing is a potentially transformative technology for engineering DNA in cells that has the potential to generate knockouts or correct certain errors or mutations in the DNA for applications such as cell or gene therapies.
Compared with currently-available gene editing methodologies such as CRISPR/Cas9, which creates ‘cuts’ in the gene that can lead to unintended adverse or negative effects, this new technology allows for precise gene editing without introducing these genomic changes that could lead to deleterious effects in patients.
https://www.ddw-online.com/will-the-next-generation-of-car-t-cells-be-modified-using-base-editing-1043-202008/
Homocitrullination of lysine residues
mediated by MDSCs in the tumour
environment makes an excellent target for
cancer Immunotherapy
Lindy Durrant, Professor of Cancer
Immunotherapy, University of Nottingham
(CONFIRMED)
This news may be of interest to someone! ;-)
Cerevel Therapeutics Announces Positive Topline Results for CVL-231 in Phase 1b Clinical Trial in Patients with Schizophrenia
https://finance.yahoo.com/news/cerevel-therapeutics-announces-positive-topline-103000730.html
25.43+12.86 (+102.27%)
As of 11:24AM EDT. Market open.
Sorry, I meant $1.8 billion. Rushing out and not checking what I was typing.
Hopefully Scancell can do a similar presentation next year for Scib and Modi.
We additionally have covidity and numerous monoclonal antibodies so what could our valuation be in time if we have some success?
Excellent results in those photos.
https://ir.replimune.com/static-files/f4fe3349-e082-4d41-94a1-106ce7e78a23
https://replimune.com/pipeline/
$1.8 million valuation
Thanks Bobbust
https://www.share-talk.com/traders-cafe-with-zak-mir-sunday-roast-june-27th-2021-vox-markets/#gs.4x7iug
8m 50s
Cell-free RNA (cfRNA) is a promising analyte for cancer detection. However, a comprehensive assessment of cfRNA in individuals with and without cancer has not been conducted. We perform the ?rst transcriptome-wide characterization of cfRNA in cancer (stage III breast [n = 46], lung [n = 30]) and non-cancer (n = 89) participants from the Circulating Cell-free Genome Atlas (NCT02889978). Of 57,820 annotated genes, 39,564 (68%) are not detected in cfRNA from non-cancer individuals. Within these low-noise regions, we identify tissue- and cancer-speci?c genes, de?ned as “dark channel biomarker” (DCB) genes, that are recurrently detected in individuals with cancer. DCB levels in plasma correlate with tumor shedding rate and RNA expression in matched tissue, suggesting that DCBs with high expression in tumor tissue could enhance cancer detection in patients with low levels of circulating tumor DNA. Overall, cfRNA provides a unique opportunity to detect cancer, predict the tumor tissue of origin, and determine the cancer subtype.
https://www.nature.com/articles/s41467-021-22444-1.epdf?sharing_token=gjc4inkm4abKfUUoL0ssYNRgN0jAjWel9jnR3ZoTv0Przg0e8LFKJo2Mamg0E7z6OxCF3esDiwOpDJZxkt8_8MZfZnyF5oVHLwi-4LzJ1Bj3Q0UmoknNk74IGUAD8oqVao12kkMabYyuAdvxlo8K62eSnsjMxxEZ2yGbM-Na9GA%3D
Fc-silent investigational monoclonal antibody that binds to TIGIT
https://www.businesswire.com/news/home/20210623005890/en/Anti-TIGIT-Domvanalimab-Based-Combinations-Showed-Encouraging-Clinical-Activity-in-People-with-Metastatic-PDL1-High-Non-Small-Cell-Lung-Cancer-at-First-Interim-Analysis-of-Arcus-Biosciences%E2%80%99-Randomized-Phase-2-ARC-7-Study#.YNOVmOyicEc.twitter
Thanks WTP,
I agree with Trinity
Trinity Delta view: Scancell is well funded to deliver on the undoubted potential of its three novel inter-related technology platforms: ImmunoBody, Moditope, and AvidiMab. Although the COVIDITY programme provides a high visibility showcase, we see a greater, longer-term, value in their applicability as treatments for many types of solid tumours. For example, ImmunoBody vaccines target dendritic cells and, importantly, stimulate both CD4 and CD8 T cells. These cancer vaccines can used as monotherapy or in combinations, with, say, checkpoint inhibitors.
Prof Lindy Durrant, Founder and Chief Scientific Officer, Scancell, commented: “We believe that the combination of cross-reactive VNAbs with durable memory responses against the conserved N protein may confer an added advantage by eliciting potent T cells that can destroy cells infected with any of the variant viruses, providing an extra layer of protective surveillance.”
https://www.calculuscapital.com/phase-1-clinical-trial-planned-in-south-africa-and-uk-for-scancells-novel-bivalent-covid-19-vaccine/
As Ray said, we would need a Big Pharma. Maybe someone like Novartis. AZ took the Jenner vaccine early;
The potential vaccine entered Phase I clinical trials last week to study safety and efficacy in healthy volunteers aged 18 to 55 years, across five trial centres in Southern England. Data from the Phase I trial could be available next month. Advancement to late-stage trials should take place by the middle of this year.
AstraZeneca and the University of Oxford today announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at preventing COVID-19 infection from SARS-CoV-2.
https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-and-oxford-university-announce-landmark-agreement-for-covid-19-vaccine.html
India’s ZyCoV-D set to become world’s first DNA Covid vaccine as govt approval likely soon. Gujarat-based Zydus Cadila has told Modi govt that it could apply for emergency use authorisation for ZyCoV-D vaccine in the next 10-12 days.
https://theprint.in/health/indias-zycov-d-set-to-become-worlds-first-dna-covid-vaccine-as-govt-approval-likely-soon/680204/
True Burble.
If a bad new variant appears then we could be very popular!
Our next generation COVID-19 vaccine has the potential to work alongside currently approved vaccines by protecting the population against new variants of SARS-CoV-2.
The paper shows that SN15 elicits strong pro-inflammatory T-cell responses to both the N and S proteins, with these responses being significantly enhanced by fusing the nucleocapsid sequence to a modified Fc utilising Scancell's AvidiMab(TM) technology.
Bermudashorts22 Jun '21 - 08:38 - 40340 of 40343
0 1 0
TF,
There are a number of companies offering needle free injection devices which use liquid jets to penetrate the skin. It may be that Scancell will use one of these but as Inan points out there are other methods too. Take a look at a company called PharmaJet, their Stratis needle free device is used for nucleic acid vaccines, has FDA clearance and is already being used in several other covid vax trials.
pharmajet.com/
In contrast to the antibody responses, the T cell responses did not seem to be impacted by
variations between the virus strains (Figure 6F). Splenocytes from mice immunised with
either the original Lineage A vaccine or the B.1.351 (Beta) vaccine were stimulated ex vivo
with RBD and N peptide pools derived from the original sequence. T cell responses specific
for RBD and N were detected with little difference between the response induced by the
different vaccine constructs. These results suggest that mutations in the B.1.351 (Beta)
variant have less impact on the T cell responses.